0001127602-17-010311.txt : 20170303
0001127602-17-010311.hdr.sgml : 20170303
20170303182229
ACCESSION NUMBER: 0001127602-17-010311
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170302
FILED AS OF DATE: 20170303
DATE AS OF CHANGE: 20170303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSULET CORP
CENTRAL INDEX KEY: 0001145197
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 043523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 TECHNOLOGY PARK
STREET 2: SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
BUSINESS PHONE: 978-600-7000
MAIL ADDRESS:
STREET 1: 600 TECHNOLOGY PARK
STREET 2: SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zakrzewski Joseph S
CENTRAL INDEX KEY: 0001331852
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33462
FILM NUMBER: 17665838
MAIL ADDRESS:
STREET 1: 110 ALLEN ROAD
CITY: LIBERTY CORNER
STATE: NJ
ZIP: 07938
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2017-03-02
0001145197
INSULET CORP
PODD
0001331852
Zakrzewski Joseph S
C/O INSULET CORPORATION
600 TECHNOLOGY PARK DRIVE, SUITE 200
BILLERICA
MA
01821
1
Common Stock
2017-03-02
4
M
0
9520
18.75
A
37369
D
Common Stock
2017-03-02
4
M
0
18480
7.06
A
55849
D
Common Stock
2017-03-02
4
M
0
4000
14.48
A
59849
D
Common Stock
2017-03-02
4
M
0
4000
20.90
A
63849
D
Common Stock
2017-03-02
4
M
0
4000
17.75
A
67849
D
Common Stock
2017-03-02
4
S
0
4000
48.031
D
63849
D
Common Stock
2017-03-02
4
S
0
13721
46.3133
D
50128
D
Common Stock
2017-03-02
4
S
0
22279
46.9907
D
27849
D
Stock Option (Right to Buy)
18.75
2017-03-02
4
M
0
9520
0
D
2018-05-08
Common Stock
9520
0
D
Stock Option (Right to Buy)
7.06
2017-03-02
4
M
0
18480
0
D
2019-07-30
Common Stock
18480
0
D
Stock Option (Right to Buy)
14.48
2017-03-02
4
M
0
4000
0
D
2020-06-01
Common Stock
4000
0
D
Stock Option (Right to Buy)
20.90
2017-03-02
4
M
0
4000
0
D
2021-05-12
Common Stock
4000
0
D
Stock Option (Right to Buy)
17.75
2017-03-02
4
M
0
4000
0
D
2022-06-01
Common Stock
4000
0
D
Includes 3,810 restricted stock units granted on May 11, 2016, which vest on April 30, 2017; 1,000 restricted stock units granted on June 2, 2014, which vest on April 30, 2017; and 2,020 restricted stock units granted on May 13, 2015, which vest 50% of the total units on April 30, 2017 and 50% of the total units on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practiable following a vesting date.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $45.65 to $46.645. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $46.66 to $47.54. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a three-year vesting period with 50% of the total award vesting one year after the grant date, 25% of the total award vesting two years after the grant date and 25% of the total award vesting three years after the grant date, subject to continued service as a director or consultant.
This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.
This option shall vest as to 100% of the total award on April 30, 2017, subject to continued service as a director or consultant.
This option is subject to a three-year vesting period with 50% of the total award vesting on April 30, 2013, 25% of the total award vesting on April 30, 2014 and 25% of the total award vesting on April 30, 2015, subject to continued service as a director or consultant.
/s/ David Colleran, attorney-in-fact
2017-03-03